Esperion Therapeutics advances research focus on PSC treatment

Traders Union
All News
Market Voices
Esperion advances PSC research

Top Stories

Editors' Picks

Stocks

Crypto

Financial News

Currencies

Commodities

Market Voices

Companies

Regulators

Central Banks

17.10.2025

Esperion Therapeutics advances research focus on PSC treatment — @EsperionInc: Esperion advances PSC research

Esperion Therapeutics is renewing its commitment to tackling primary sclerosing cholangitis (PSC), a disease affecting thousands of individuals in the U.S. and Europe. With no currently approved therapies, Esperion focuses on research to explore new treatment possibilities for PSC.

This commitment underscores the company's dedication to improving the lives of patients and families dealing with this challenging condition. Esperion's pipeline aims to bring hope through scientific innovation, addressing an unmet medical need and advancing the search for effective solutions.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

Editor's Picks for You

Where World Cup 2026 stars invest: Football clubs, technology and crypto

By Pavlo Kot
22 min ago

Where World Cup 2026 stars invest: Football clubs, technology and crypto

Editors' Picks

CBDC ban: Why the U.S. does not need a digital dollar

By Eugene Komchuk
Yesterday

CBDC ban: Why the U.S. does not need a digital dollar

Editors' Picks

Bitcoin price prediction and Bollinger Bands: Can BTC recover after falling to $63,000?

By Mikhail Vnuchkov
23.06.2026

Bitcoin price prediction and Bollinger Bands: Can BTC recover after falling to $63,000?

Editors' Picks

All Editors' Top Picks

Latest Esperion News

Esperion Therapeutics launches recruitment drive to advance cardiovascular care

By Ashutosh Sureka
22.06.2026

Esperion Therapeutics launches recruitment drive to advance cardiovascular care

Companies

New pediatric cholesterol study data released by Esperion Therapeutics at European Atherosclerosis Society event

By Igor Krasulya
26.05.2026

New pediatric cholesterol study data released by Esperion Therapeutics at European Atherosclerosis Society event

Companies

Esperion Therapeutics estimates U.S. heart failure costs at 46B dollars a year, urges therapy optimization

By Dmytro Kharkov
14.05.2026

Esperion Therapeutics estimates U.S. heart failure costs at 46B dollars a year, urges therapy optimization

Companies

All Esperion News

Pavlo Kot
22 min ago

Where World Cup 2026 stars invest: Football clubs, technology and crypto

Eugene Komchuk
Yesterday

CBDC ban: Why the U.S. does not need a digital dollar

Mikhail Vnuchkov
23.06.2026

Bitcoin price prediction and Bollinger Bands: Can BTC recover after falling to $63,000?

Oleg Tkachenko
22.06.2026

FIFA World Cup on blockchain: Where football meets crypto

Pavlo Kot
21.06.2026

Aliens, Satoshi, and Bitcoin: How the extraterrestrial theory emerged

Hanna Syniavska
8 min ago

Crypto mixers are emerging tools for digital privacy, Henri Arslanian notes

Dmytro Kharkov
23 min ago

Ursula von der Leyen: Ukraine offers new investment opportunities as future single market member

Andreas Kristo
38 min ago

Tracy Shuchart: Chinese banks curb retail gold trading amid volatility

Elena Nikulina
53 min ago

Major Chinese banks halt precious metals services to retailers, Peter Spina notes

Ivan Andriyenko
53 min ago

Simon Taylor: Stripe valued at $159 billion, ranks fourth among private companies globally

Weekly Top Bonuses

Capitalcore

up to $2,500
deposit bonus for all clients

Your capital is at risk.

Top News

Pavlo Kot
22 min ago

Where World Cup 2026 stars invest: Football clubs, technology and crypto

Where World Cup 2026 stars invest: Football clubs, technology and crypto

Igor Krasulya
1 hour ago

U.S. futures advance as AI jitters fade after chip updates

U.S. futures advance as AI jitters fade after chip updates

Andrey Mastykin
2 hours ago

Brent falls to prewar levels as Middle East supply returns

Brent falls to prewar levels as Middle East supply returns

Eugene Komchuk
19 hours ago

Binance ready to choose another EU country for MiCA license

Binance ready to choose another EU country for MiCA license

Olga Shendetskaya
20 hours ago

Trump says Strait of Hormuz will remain open and toll-free

Trump says Strait of Hormuz will remain open and toll-free

Top 5 companies for you

United States

Live News

Mykhailo Ihnatenko
Now

Rolls-Royce hits all-time high as bullish momentum persists

Mykhailo Ihnatenko
Now

Solana shows resilience as Bitcoin struggles

Mykhailo Ihnatenko
Now

Crypto winter fears grow as Bitcoin hits 52-week low

Anton Kharitonov
Now

Google corrects after rally despite strong Alphabet results

Anton Kharitonov
Now

Microsoft remains under pressure from AI spending despite Azure growth

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.